Quanterix has named Paul Chapman as its new president and CEO. In the latter role, Chapman replaces Martin Madaus who will remain as executive chairman of the privately held firm's board of directors.
In his new roles, Chapman will oversee the commercialization of Quanterix's Simoa technology (see related story, this issue). He joins Quanterix from EMD Millipore, where he was vice president of its BioPharm Process Solutions business. Prior to joining Millipore, he was vice president of hospital solutions for Roche Near Patient Testing in Austria. Chapman was also the international business development manager at Roche Molecular Diagnostics for blood screening and held a number of sales and marketing positions at Roche Diagnostics Canada, where he began his career in 1993.
Chapman holds a BSc in microbiology from the University of Western Ontario, a BSc in immunology from the University of Guelph in Ontario, and graduated from the marketing management program at the Richard Ivy School of Business in London, Ontario.